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ABSTRACT

Hypercholesterolemia is a highly prevalent disease often treated with
statin therapy. Statins lower serum cholesterol level by increasing the level
of low-density lipoprotein receptors (LDLR) in liver cells, which bind to and
remove low-density lipoprotein cholesterol (LDL-C). However, up to 39% of
individuals fail to meet LDL-C goals. There are FDA approved alternatives to
statins such as Evolocumab (PCSK9 inhibitor), as well as Mipromersen
(oligonucleotide inhibitor of ApoB synthesis) and Lomitapide (MTTP
inhibitor). Evolocumab is cost prohibitive and, along with statins, has little to
no

effect

in

patients

with

LDLR

mutations

such

as

Familial

Hypercholesterolemia (FH), which is an inherited metabolic disease caused
by decreased functionality of LDLRs.

Additionally, Mipromersen and

Lomitapide have FDA hepatotoxic warnings. Therefore, there is a need for
new drug that lowers cholesterol levels independently from the LDLR
pathway.

vii

In order to find an alternative compound with less toxicity, a small
molecule screening was conducted using ELISA to measure changes in
concentration of the major protein component of LDL-C, Apolipoprotein B,
within the culture medium of iPSC-derived hepatocytes. We have access to
nearly 120,000 novel molecules from the South Carolina Compound
Collection (SC3) and tested a 10,000 compound chemically diverse subset of
this library. Using human iPSC-derived hepatocytes, we aimed to identify
novel compounds that reduce serum LDL-C level independent from the LDLR
pathway. Through the course of the screening, we identified 11 compounds
that reduced Apolipoprotein B levels, five of which are hypothesized to
function through an LDLR-independent mechanism.

viii

INTRODUCTION

Familial

Hypercholesterolemia

(FH)

is

an

inherited

form

of

hyperlipidemia resulting from loss of function mutations to the low-densitylipoprotein receptor (LDLR) gene.1,

2

When the organ size is taken into

account, the liver produces the greatest amount of LDLRs in the body.3 One
function of the LDLR is believed to be regulation of the secretion and
degradation of Apolipoprotein B (ApoB), which is used by hepatocytes to form
the protein core of low-density lipoproteins (LDL).4, 5 Following its formation
in the liver, very-low-density lipoproteins (VLDL) are secreted into the
bloodstream where it is converted to LDL through the action of triacylglycerol
lipase.5
Every VLDL and LDL particle contains one molecule of ApoB, which
transports approximately 1600 molecules of cholesterol.1, 6 LDLRs have high
affinity for LDL and are able to cycle multiple times into the cell and back to
internalize LDL.3 Without the ability to gauge serum LDL-C levels through
functional LDLRs, patients with FH show higher levels of ApoB being
secreted and reduced rates of clearance, resulting in increased levels of
VLDL, and therefore LDL, found in circulation.5, 7
FH

occurs

in

heterozygous

and

homozygous

forms.

While

heterozygosity is more prevalent, affecting approximately 1:500 individuals,
the phenotype of homozygous individuals is more severe.1,

2

Homozygous
1

individuals have LDL-C levels that are two-to-ten times higher than
unaffected individuals1,

2, 8

and develop severe early onset cardiovascular

diseases in childhood that can result in sudden cardiac death by their second
decade of life if left untreated.2 Incidence of heart attack is known to
increase proportionately with levels of plasma LDL-C.3, 4
Many heterozygous individuals can be treated successfully with
cholesterol lowering drugs such as statins and PCKS9 inhibitors, which
upregulate

LDLR

transcription

and

LDLR

protein

stability,

respectively.9 Individual responses to statins vary widely, however, and at
least 20% of patients, on average, do not meet their LDL-C goals.8, 10 There
are several different factors which underlie statin resistance, including
genetics, comorbidities, and interactions with other drugs.11 Additionally,
these therapies are ineffective in treating patients with homozygous FH
(HoFH) due to the absence of functional LDLRs.10, 11
Therapies that target VLDL production result in a reduction of LDL-C
in HoFH.9 Two such therapies are Lomitapide and Mipromersen, which
interferes with the production of VLDL and ApoB respectively. 12,

13, 14

However, both Lomitapide and Mipromersen have FDA warnings for
detrimental side effects including increased risk of liver damage and fatty
liver disease.13, 14 As such, there are currently no therapies for individuals
with HoFH that are known to be safe and effective. New therapeutic

2

advances need to be developed and employed not only in cases of FH, but also
in cases where the current standard of care may fall short.
Induced pluripotent stem cells (IPSC) have the potential to
revolutionize new therapeutic opportunities.
unsuitable

for

studying

complex

Primary hepatocytes are

functions

because

they

rapidly

dedifferentiate in culture and lose key hepatic functions.9, 15 IPSCs, however,
provide an alternative to primary hepatocytes. IPSCs are somatic cells (e.g.
skin, fibroblasts, blood) that have been reprogrammed to a pluripotent,
embryonic stem cell state through the addition of 4 transcription factors,
known as the Yamanaka factors (OCT4, SOX2, and either NANOG & LIN28
or KLF4 & MYC),16 and they can be generated from either healthy or
diseased, patient specific cells. IPSCs are useful as an alternative to primary
hepatocytes because the IPSCs can be directed to differentiate into,
potentially, any somatic cell type through cell culture differentiation
including hepatocyte-like cells.16,

17

Patient specific IPSCs generated from

diseased cells have been shown to retain characteristics of that disease after
differentiation.8, 18 Use of patient specific IPSCs allows for an inexhaustible
source of disease-modeling cells that can be used to study the biomechanics of
the disease, as well as investigating potential therapies. IPSCs have many
functions in medical research, including disease modeling, drug discovery,
and preclinical trial testing.9, 16, 18, 19 The inducible nature of IPSCs makes
them useful in answering disease specific questions.
3

Previous research in our lab has demonstrated the ability to
successfully utilize both wild-type iPSC-derived hepatocyte-like cells (K3
iPSCs) and patient-derived HoFH iPSC-derived hepatocyte-like cells as part
of a compound screening platform.9 Cayo et al have shown that the
pathophysiology of FH can be recapitulated in patient-derived IPSCs, and
that these cells are suitable for compound screening.7, 9 During this previous
screening of a repurposing library, cardiac glycosides were identified as
having potential use as a drug therapy in cases of hypercholesterolemia, in
particular for cases of FH.
It is known that there are alternative routes to the LDLR pathway
that are employed by the liver to clear LDL-C in excess of what can be
cleared through the LDLR pathway.6

Cardiac glycosides, along with the

currently approved therapies, Lomitapide and Mipromersen, function outside
of the LDLR pathway to reduce LDL-C levels by disrupting the production of
either Apolipoprotein B or VLDL.9, 13, 14 However, due to the detrimental side
effects associated with the currently approved drug therapies, it is necessary
to identify novel compounds that function in lowering levels of LDL-C by
effecting either the production, secretion, or clearance of Apolipoprotein B or
VLDL.
In this research, we aim to identify small molecules within the RS
subset of the SC3 library of compounds that will reduce the level of
Apolipoprotin B protein in the culture medium of wild-type IPSC-derived
4

hepatocyte-like cells (aim 1), and to identify which of those primary
compounds function

independently

of

the

LDLR

pathway

to

lower

Apolipoprotein B within the culture medium (aim 2).

5

MATERIALS AND METHODS

Cell Culture
iPS cells were cultured on p100 plates coated with E-Cadherin Substrate
(StemAdhere) under hypoxic conditions (4% O2/5% CO2) at 37°C in mTeSR1
culture medium supplemented with z-FGF.

The culture medium was

changed daily, and the cells were passaged approximately every 3-5 days.

Hepatocyte Differentiation
Differentiation of iPS cells was done on Matrigel coated 96-well tissue culture
plates. The cells were cultured in mTeSR1 medium for approximately 24
hours after plating to allow the wells to reach approximately 85-90%
confluency at which point differentiation may be initiated.

To begin

differentiation, the cells were cultured for two days (differentiation days 1-2)
in the following medium: RPMI + B27 (without insulin) + Activin A + BMP4
+ FGF-2 under normoxic conditions (ambient O2/5% CO2) at 37°C.

For

differentiation days 3-5, the cells were cultured in the following medium:
RPMI + B27 (without insulin) + Activin A under normoxic conditions
(ambient O2/5% CO2) at 37°C. At differentiation day 5, before replacing the
culture medium, the cells were treated with Versene/EDTA briefly to prevent
the monolayer from detaching from the well and aggregating.

For

differentiation days 6-10, the cells were cultured in the following medium:
6

RPMI + B27 (with insulin) + BMP4 + FGF-2 under hypoxic conditions (4%
O2/5% CO2) at 37°C. For differentiation days 11-15, the cells were cultured in
the following medium: RPMI + B27 (with insulin) + HGF under hypoxic
conditions (4% O2/5% CO2) at 37°C. For differentiation days 16-20, the cells
were cultured in the following medium: HCM + Oncostatin M under normoxic
conditions (ambient O2/5% CO2) at 37°C.

South Carolina Compound Collection (SC3) Library
The full SC3 library contains 120,000 chemically diverse small, drug-like
compounds. A complex algorithm is utilized to break this full library up into
smaller libraries. For the purposes of this screening, we are utilizing the
Representative Set (or "RS set") of 10,000 unique compounds that are
chemically representative of the 120,000 compounds found in the full
library.

Compound Treatment
At differentiation day 21, exactly 24 hours after changing the culture medium
on differentiation day 20, the culture medium was collected and transferred
to new 96-well plates, sealed, and stored at -20°C until ready for further
testing. These samples were deemed the “pre-treatment samples”. Following
the collection of the pre-treatment samples, the cells were treated with
either: compound or DMSO (vehicle only) depending on if the well was
7

designated as experimental or control. These cells were cultured for 24 hours
under normoxic conditions (ambient O2/5% CO2) at 37°C. At differentiation
day 22, exactly 24 hours after then application of compound to the cells, the
culture medium was collected again and transferred to new 96-well plates,
sealed, and stored at -20°C until ready for further testing. These samples
were deemed the “post-treatment samples”.

Cell Viability
Following collection of post-treatment samples from validation screening
plates, cell viability was determined through the use of a commercially
available cell viability assay (Cell-Titre Glo).

ELISA
Concentrations of ApoB within the pre and post treatment samples were
determined through the use of a Human ApoB100 ELISA assay kit from
Mabtech. The assays were conducted in 96-well format. A standard curve
was included on each plate using ApoB protein from the ELISA kit. This
provided a measure of comparison to determine the concentration of ApoB
present within the samples through the use of a four-parameter logistic (4PL)
regression curve.

8

Statistical Analysis
The concentration of Apolipoprotein B within each sample, as determined by
ELISA, was used to determine the [post-treatment sample] : [pre-treatment
sample] ratio for each compound.

This Apolipoprotein B ratio was

normalized to the average Apolipoprotein B ratio of DMSO only control
samples. Due to the absence of replicates in the primary screening and the
large number of samples per plate, we conducted z-score analysis on a plate
to plate basis to identify compounds that reduced concentrations of
Apolipoprotein B significantly compared to the mean reduction.20 We chose a
threshold of z-score ≤ -3.0, based on the 3-sigma rule.21

Compounds of

interest from the primary screening were validated with replicates (n=4). In
analyzing the results obtained from validation screening, a student t-test was
utilized to determine significance (p ≤ 0.05).

A student t-test was also

utilized to determine compounds that significantly lowered cell viability (p ≤
0.05). Compounds of interest from the validation screening in WT K3 iPSCderived hepatocyte-like cells were then validated with replicates (n=4) in JD4
HoFH iPSC-derived hepatocyte-like cells. In analyzing the results obtained
from JD compound screening, a student t-test was utilized to determine
significance (p ≤ 0.05).

A student t-test was also utilized to determine

compounds that significantly lowered cell viability (p ≤ 0.05).

9

RESULTS

Experimental Overview
Prior to screening the entire RS subset, the first 1,000 compounds were
screened to test our approach. The first 1,000 compounds of the RS subset
are designated as the RS Lite subset and were used for this purpose as they
provide a representation of the compounds within the RS subset.

No

replicates were used for the primary screening of the RS Lite subset or the
RS subset due to the quantity of compounds screened. Wild-type K3 iPSCderived hepatocyte-like cells were used because they have functional LDLRs
which allowed for identification of all compounds within the RS subset that
lowered Apolipoprotein B levels secreted into the culture medium.
Wild-type K3 iPSC-derived hepatocyte-like cells were differentiated in

Figure 1: Experimental Design Overview
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96-well format, and samples of culture medium were collected before and
after the 24-hour compound treatment. The level of Apolipoprotein B within
the culture medium was determined by ELISA for the pre- and posttreatment samples and the concentrations were used to determine the [posttreatment]:[pre-treatment] ratio of Apolipoprotein B within the culture
medium (Figure 1). The ratio of Apolipoprotein B was normalized to the
average ratio of Apolipoprotein B within the culture medium of DMSO only
treated control cells.
Z-factor analysis was conducted for our ELISA assay to determine the
efficiency of the assay to distinguish between a positive control (mature iPSCderived hepatocyte-like cells) and a
negative control (undifferentiated
iPS cells).

The z-factor (Z’) is

determined by using the formula
Z’ =

!(!!! !!!! )
!!! !!!!

; where 𝜎!! and 𝜎!!

are the standard deviations for

Figure 2: Z-Factor Analysis of ELISA Assay
Z-Factor Analysis shows the ability of our ELISA
to distinguish between positive (blue) and
negative (orange) controls.

positive and negative controls respectively, and 𝜇!! and 𝜇!! are the averages
for positive and negative controls respectively. Readings between 0.5 and 1.0
indicate that the assay is excellent for high throughput screening
applications.22 The z-factor reading for our assay was 0.73 (Figure 2).
Primary screening of the RS Lite subset using wild-type K3 iPSCderived hepatocyte-like cells, yielded 25 compounds that significantly lowered
11

Apolipoprotein B secretion in the culture medium as determined by z-score
analysis using a more lenient threshold of a z-score of -2.0, which corresponds
to a confidence interval of approximately 95.5% (Primary screening
normalized ratios and z-scores for RS Lite set are included in Figure 3). We
chose to utilize a z-score of -2.0 rather than a z-score of -3.0 as the threshold
for screening the first 1,000 compounds because we wanted to ensure that we
were identifying all possible compounds that were likely to significantly lower
Apolipoprotein B within the culture medium.
Validation screening with replicates (n=4) of the 25 compounds
identified in the RS Lite primary screening

resulted in four compounds

which reduced Apolipoprotein B secretion significantly (p ≤ 0.05) compared to
DMSO-only treated control cells (Figure 4A). The four reproducible hits
were all compounds that had z-scores ≤ -3.0 when originally tested in the
primary screening.
Cell viability analysis of the 25 compounds revealed that two of the
four compounds identified in the validation screening had a significant
negative impact to cell viability (p ≤ 0.05) (Figure 4B).

This left two

compounds from the RS Lite subset which significantly (p ≤ 0.05) reduced
levels of Apolipoprotein B in the culture medium without a significant
decrease in cell viability.

12

A.

B.
Figure 3: Primary Screening Data from RS subset of SC3 Library (A) Graph showing the [Posttreatment]:[Pre-treatment] Apolipoprotein B ratios, normalized to DMSO control cells, identified from
culture medium samples from the primary screen in wild-type K3 IPSC-derived hepatocyte like cells.
Each point represents the effect of one compound within the RS subset of the SC3 library. (B) Graph
showing z-scores correlating to the effect of each compound on the level of Apolipoprotein B secreted into
the culture medium. Each point represents one compound from within the RS subset of the SC3 library
and the red lines demarcate +/- 3.0 which we used as our threshold.
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Screening of SC3 library in WT K3 Cells
Following

successful

identification

of

compounds

that

would

significantly reduce Apolipoprotein B concentrations with the RS Lite subset,
we continued screening the remainder of the RS subset. Wild-type K3 iPSCderived hepatocyte-like cells were differentiated in 96-well format, and
samples of culture medium were collected before and after the 24-hour
compound treatment.

The level of Apolipoprotein B within the culture

medium was determined by ELISA. A ratio between [Post treatment ApoB]
and [Pre treatment ApoB] was determined for all 10,000 compounds in the
RS subset of the SC3 library (Figure 3A). Z-scores were also determined for
each compound (Figure 3B).
In screening the RS subset, we considered all compounds with z-scores
≤ -3.0 to be primary hits. This z-score corresponds to a confidence interval of
approximately 99.7%.

In analyzing the primary data, we also decided to

include 13 compounds whose z-scores fell just outside our threshold of zscores ≤ -3.0 because we could accommodate additional primary hits in the
follow-up assays. All 13 additional compounds added had z-scores between 2.7 (approximately 99.3% confidence interval) and -3.0, in addition to
reductions in Apolipoprotein B secretion of at least 25%. This resulted in 44
compounds that were considered to be primary hits, in addition to the 25
primary hits previously identified in screening the RS Lite subset of the SC3
library (the first 1,000 compounds of the RS subset) using a less stringent z14

score of z ≤ -2.0, for a total of 69 primary hits within the RS subset of the SC3
library.
These 69 compounds had Apolipoprotein B reductions ranging from
13.8% to 80.2% compared to DMSO-treated control cells.

Validation

screening of the 68 total primary hits with replicates (n=4) showed 19 total
compounds that reduced Apolipoprotein B secretion with statistical
significance (p ≤ 0.05) compared to DMSO-treated control cells (Figure 4A).

A

B
Figure 4: RS Validation Screening: (A) shows the normalized Apolipoprotin B secretion ratios
for all 68 primary hits (n=4). (B) show cell viability assay results for the same samples (n=4).
Asterisk indicates p ≤ 0.05
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In addition to the mechanistic effects of the compounds, observed
reductions in concentration of Apolipoprotein B in the culture medium could
also be attributed to a reduction in cell viability as a result of the compound
toxicity. Cell viability analysis of the primary hits showed that 11 of the 19
compounds identified in the validation screening did not have a negative
impact

on

cell

(Figure 4B).

viability
The

11

compounds that significantly
lowered

Apolipoprotein

B

concentrations in the culture
medium

of

wild-type

K3

iPSC-derived hepatocyte-like
cells

without

negatively

Compound
D-28395
D-67841
D-85697
D-67383
D-26389
D-65895
D-70514
D-70458
D-28929
A-00152
D-65600

Normalized Ratio
in WT (n=4)
0.778469746
0.683902366
0.848756691
0.685334429
0.536272923
0.607600512
0.75044936
0.6974290
0.852019837
0.787729162
0.885846075

Cell Viability
in WT (n=4)
92.88%
105.59%
102.28%
106.14%
104.92%
111.17%
105.84%
93.02%
93.45%
104.69%
99.97%

Table 1: Compounds of Interest following Validation
Compounds from the RS set that significantly lowered ApoB
levels in culture medium of WT K3 IPSC-derived
hepatocyte-like cells without decreasing the cell viability.

impacting cell viability are
listed in Table 1.

Screening in patient-derived HoFH Cells
Following the identification of compounds that lowered Apolipoprotein
B levels in cells that had functional LDLRs without decreasing cell viability,
we wanted to determine if any of those compounds of interest functioned
independently of the LDLR. To test this, we utilized iPSCs derived from a
patient, JD, who had two characterized mutations7, 23, 24 (compound
16

heterozygote) to the LDLR gene resulting in an effective homozygous FH
phenotype that has previously been shown to recapitulate the HoFH
phenotype in induced hepatocyte-like cells.7 The patient-derived IPSCderived hepatocyte-like cells were treated with 10 of the 11 compounds
previously identified in K3
cells for 24 hours following a
pre-treatment sample
collected (n=3). After the
24-hour treatment, a postA.

treatment sample was also
collected, as before. Analysis
of these samples showed that
5 of the 10 compounds tested
so far significantly reduced
Apolipoprotein B levels (p ≤
0.05) in the presence of
nonfunctional LDLRs
(Figure 5A) without

B.
Figure 5: Normalized Ratios and Cell Viability in
Patient-Derived IPS Cells (A) Average [Post-treatment
ApoB] : [Pre-treatment ApoB] ratios normalized to DMSOtreated control cells (n=3) for compounds treated on
patient-derived HoFH IPSC-derived hepatocyte-like cells.
Asterisk indicates p ≤ 0.05 (B) Cell viability normalized to
DMSO-treated control cells (n=3) for compounds treated
on patient-derived HoFH IPSC-derived hepatocyte-like
cells. Asterisk indicates p ≤ 0.05

decreasing the cell viability (Figure 5B). The compounds had reductions in
Apolipoprotein B levels ranging from 16.67% to 43.6% compared to DMSOtreated control cells.
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DISCUSSION

In conducting this research, we have identified 11 novel compounds, 5
of which we believe to function independent of the LDLR, that may have the
potential to be used in the future as therapies for patients with
hypercholesterolemia.
Previous research in our lab determined that cardiac glycosides have a
cholesterol lowering effect.9 Identification of the chemical structures of our
compounds of interest following this screening showed four of the compounds
to be chemically similar to cardiac glycosides (D-14442, D-67844, D-82034,
and D-83522).

All four of these compounds significantly lowered

Apolipoprotein B concentrations (p ≤ 0.05) within culture medium of wildtype K3 iPSC-derived hepatocyte-like cells; however, they were also observed
to reduce cell viability significantly (p ≤ 0.05). The compound D-82034 was
also tested in the patient-derived JD HoFH iPSC-derived hepatocyte-like
cells (data not shown) and was seen to significantly lower Apolipoprotein B
concentrations (p ≤ 0.05). Cell viability analysis showed 68.3% viability for
the compound D-82034 in patient-derived JD HoFH iPSC-derived hepatocytelike cells.

In the wild-type cell line, the cell viability analysis for the

glycoside-like compounds D-14442, D-67844, D-82034, and D-83522 showed
37.71%, 6.14%, 72.02%, and 73.51% cell viabilities respectively. The previous
research in our lab found that treatment with cardiac glycosides in the
18

nanomolar range was sufficient to observe significant reduction in
Apolipoprotein B concentration.9

In screening the RS subset of the SC3

library, we used 5.2 µM concentrations in our compound treatment.
Therefore, it is likely that at a lower concentration these four compounds may
not have a significant negative impact to cell viability.
The patient-derived JD HoFH iPSC-derived hepatocyte-like cells have
been shown to have nonfunctional LDL receptors that do not internalize
LDL-C.9 As a result of this, it can be hypothesized that the compounds which
were shown to lower Apolipoprotein B levels in the patient-derived JD HoFH
IPSC-derived hepatocyte-like cells (D-85697, D-67383, D-65895, and D-28395,
D-70514), function through mechanisms that are LDLR-independent. It is
likely

that

these

compounds

function

to

reduce

Apolipoprotein

B

concentrations by decreasing the production of Apolipoprotein B, increasing
the degradation of Apolipoprotein B, or interfering with the ability of
Apolipoprotein B to form lipoprotein particles, any of which would result in
decreased levels of Apolipoprotein B within the culture medium.
Additionally, there was one compound, D-70458, that was also shown
to significantly reduce Apolipoprotein B levels; however, a 69% reduction in
cell viability was observed.

Reduced cell viability was not previously

observed with this compound. It is possible that the compound has degraded
as a result of several cycles of thawing and refreezing the compound during
the course of this screen. We plan to retreat this compound on the patient19

derived cell line in the future, in addition to testing the remaining compound
that was identified in the wild-type validation screening, D-28929, that has
not yet been exposed to the patient-derived cell line.
There were eight compounds that were observed to significantly reduce
Apolipoprotein B concentrations in the culture medium of wild-type K3 iPSCderived hepatocyte-like cells but were excluded from testing in the patientderived cell line because of their impact to cell viability in the wild-type K3
iPS cell line. Four of the eight compounds excluded from screening in the
patient derived JD HoFH iPS cell line were the previously mentioned
glycoside-like compounds. In future research, dose response will be conducted
on all of the compounds identified to significantly reduce Apolipoprotein B
concentrations in wild-type K3 iPSC-derived hepatocyte-like cells to
determine if adjusting the dosage of the compound mitigates any negative
impact on cell viability.
Because the RS subset that we used in our screen was constructed to
be chemically representative of the entire SC3 library, we can return to the
full library of 120,000 compounds in the future and selectively screen other
compounds that are chemically similar to the hits that we identified in
screening the RS subset. This process could identify other compounds that
lower Apolipoprotein B concentrations that were not already identified in
screening the RS subset. Congruent results between the hits identified in the
RS screen and their respective chemically similar compounds would increase
20

our confidence in our results. It is possible that there are similar compounds
in the full library that lower Apolipoprotein B levels more dramatically or
with less effect on the cell viability that would also be of interest.
Although these compounds were identified to lower Apolipoprotein B
levels in culture medium, it is possible that the compounds within the library
are not entirely pure. Contamination of the compound could play a role in
the reduction of Apolipoprotein levels, leading to a need to determine the
purity of the compounds we identified.
Although iPSC-derived hepatocyte-like cells provided a suitable
platform for high throughput screening of a large number of compounds,
these cells don’t express the full array of mRNAs that are seen in adult
primary hepatocytes.15 This discrepancy in mRNA profiles between iPSCderived hepatocyte-like cells and primary human hepatocytes could impact
drug metabolism and efficacy. Testing the compounds of interest in primary
human hepatocytes would provide key information to better understand how
these compounds may behave in the context of the human system.
Additionally, due to their availability, we are choosing not to focus on the
glycoside-like compounds. Testing our compounds of interest in an iPS cell
line containing a mutation to the ATP1a1 gene would allow us to screen out
compounds that function through the same mechanism as cardiac glycosides
because the ATP1a1 mutation present in this cell line prevents the binding of
cardiac glycosides to their receptor.25
21

In order to determine the mechanism of action for our compounds of
interest, it is necessary to determine at which point in the pathway of
cholesterol biosynthesis and secretion the compounds exert their influence.
Conducting tests such as qRT-PCR and immunoblotting would provide
information about the levels of mRNA and protein expression for genes
related to cholesterol synthesis, such as Apolipoprotein B, PCSK9, and
MTTP, which would be useful in determining where along the pathway the
compounds are acting and whether they act before or after transcription or
translation. Structure-activity relationship (SAR) testing would also help to
elucidate more specifically the action by which the compound reduces
Apolipoprotein B by comparing the chemical structures of our compounds of
interest to other structures with known mechanisms.

This could provide

some insight into specific targets for the compounds of interest within
cellular pathways. Additionally, comparison of our compounds of interest to
known compounds could provide information regarding adverse effects
associated with specific structural components present in our compounds of
interest. Further information regarding potential toxic side effects of our
compounds of interest could be obtained by testing the compounds in other
major cell types such as cardiomyocytes or neural cells. Treatment of our
lead compounds in mice with humanized livers would allow for identification
of the compounds’ effectiveness in a more complex system as well as allowing

22

for identification of potential adverse effects of the compounds on the level of
organ systems and the overall impact to the animal.
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